References

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Clinical Review Report: adalimumab (Humira) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr.

Cover of Clinical Review Report: adalimumab (Humira)

Clinical Review Report: adalimumab (Humira) [Internet].

Show details

Contents

< PrevNext >

References

1.: Fast facts: the impact of IBD in Canada 2012 [Internet]. Toronto: Crohn’s and Colitis Foundation of Canada; 2012. [cited 2016 Jan 25]. Available from: http://www.isupportibd.ca/pdf/ccfc.ca-impact-report-fast-facts.pdf
2.: ^PrHumira® (adalimumab): 40 mg in 0.8 mL sterile solution (50 mg/mL) subcutaneous injection [product monograph]. St-Laurent (QC): AbbVie Corporation; 2015 Jul 3.
3.: Clinical study report: M06-826. A multicenter, randomized, double-blind, placebo controlled study of the human anti-TNF monoclonal antibody adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis [CONFIDENTIAL internal manufacturer’s report]. Abbott Park (IL): Abbott Laboratories; 2012 Dec.
4.: Clinical study report: M06-827. A multicenter, randomized, double-blind, placebo controlled study of the human anti-TNF monoclonal antibody adalimumab for the induction and maintenance of clinical remission in subjects with moderately to severely active ulcerative colitis [CONFIDENTIAL internal manufacturer’s report]. Abbott Park (IL): Abbott Laboratories; 2012 Dec.
5.: Suzuki Y, Motoya S, Hanai H, Matsumoto T, Hibi T, Robinson AM, et al. Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. J Gastroenterol [Internet]. 2014 Feb [cited 2015 Nov 16];49(2):283–94. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3925299 [PMC free article: PMC3925299] [PubMed: 24363029]
6.: e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2009 -. Simponi, golimumab; 2013 Sep 19 [cited 2016 Jan 28]. Available from: https://www.e-therapeutics.ca Subscription required.
7.: e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2009 -. Remicade, infliximab; 2013 Aug 26 [cited 2016 Jan 26]. Available from: https://www.e-therapeutics.ca Subscription required.
8.: e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2009 -. Humira, adalimumab; 2014 Jan 17 [cited 2016 Jan 26]. Available from: https://www.e-therapeutics.ca Subscription required.
9.: e-CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2009 -. Entyvio, vedolizumab; 2015 Jan 25 [cited 2016 Jan 28]. Available from: https://www.e-therapeutics.ca Subscription required.
10.: Reinisch W, Sandborn WJ, Hommes DW, D’Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011 Jun;60(6):780–7. [PubMed: 21209123]
11.: Reinisch W, Sandborn WJ, Panaccione R, Huang B, Pollack PF, Lazar A, et al. 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants. Inflamm Bowel Dis. 2013 Jul;19(8):1700–9. [PubMed: 23665965]
12.: CDR submission: Humira (adalimumab) for ulcerative colitis, 40 mg in 0.8 mL sterile solution (50 mg/mL). Company: AbbVie Corporation [CONFIDENTIAL manufacturer’s submission]. Dorval (QC): AbbVie Corporation; 2015 Oct 27.
13.: Health Canada reviewer’s report: Humira (adalimumab) [CONFIDENTIAL internal report]. Ottawa: Therapeutics Products Directorate, Health Canada; 2013 Nov 21.
14.: Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D’Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012 Feb;142(2):257–65. [PubMed: 22062358]
15.: Sandborn WJ, Colombel JF, D’Haens G, van Assche G, Wolf D, Kron M, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther. 2013 Jan;37(2):204–13. [PubMed: 23173821]
16.: Wolf D, D’Haens G, Sandborn WJ, Colombel JF, van Assche G, Robinson AM, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014 Sep;40(5):486–97. [PubMed: 25041859]
17.: Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease. Aliment Pharmacol Ther [Internet]. 2009 May 1 [cited 2016 Jan 26];29(9):1032–41. Available from: 10.1111/j.1365-2036.2009.03966.x [PubMed: 19222413] [CrossRef]
18.: Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001 Jul;33(5):350–7. [PubMed: 11491194]
19.: Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. PharmacoEconomics. 1999 Feb;15(2):141–55. [PubMed: 10351188]
20.: Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am J Manag Care. 2008 Apr;14(4):239–53. [PubMed: 18415967]
21.: Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s Relapse Prevention Trial Study Group. Gastroenterology. 1994 Feb;106(2):287–96. [PubMed: 8299896]
22.: Clinical Study Report: M10-223. A multicenter, open-label study of the human anti-TNF monoclonal antibody adalimumab to evaluate the long-term safety and tolerability of repeated administration of adalimumab in subjects with ulcerative colitis [CONFIDENTIAL internal manufacturer’s report]. Abbott Park (IL): Abbott Laboratories; 2009 Dec 31.
23.: Lewis JD, Chuai S, Nessel L, Lichtenstein GR, Aberra FN, Ellenberg JH. Use of the non-invasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis [Internet]. 2008 Dec [cited 2015 Nov 19];14(12):1660–6. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2597552/pdf/nihms65682.pdf [PMC free article: PMC2597552] [PubMed: 18623174]
24.: Cooney RM, Warren BF, Altman DG, Abreu MT, Travis SP. Outcome measurement in clinical trials for ulcerative colitis: towards standardisation. Trials. 2007;8:17. [PMC free article: PMC1919394] [PubMed: 17592647]
25.: Guyatt G, Mitchell A, Irvine EJ, Singer J, Williams N, Goodacre R, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology. 1989 Mar;96(3):804–10. [PubMed: 2644154]
26.: Pallis AG, Mouzas IA, Vlachonikolis IG. The inflammatory bowel disease questionnaire: a review of its national validation studies. Inflamm Bowel Dis. 2004 May;10(3):261–9. [PubMed: 15290922]
27.: Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care. 1992 Jun;30(6):473–83. [PubMed: 1593914]
28.: Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006 Apr;54(4):685–704. [PubMed: 16546593]
29.: Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005 Oct;11(10):909–18. [PubMed: 16189421]
30.: Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, et al. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3. Am J Gastroenterol. 2014 Nov [cited 2016 Jan 26];109(11):1771–80. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223868 [PMC free article: PMC4223868] [PubMed: 25155227]
31.: Archer R, Tappenden P, Ren S, Martyn-St James M, Harvey R, Besarir H, et al. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262) [ID695]. Sheffield, UK: University of Sheffield; 2014. [PMC free article: PMC4904186] [PubMed: 27220829]
32.: Thorlund K, Druyts E, Toor K, Mills EJ. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs. Expert Rev Gastroenterol Hepatol. 2015 May;9(5):693–700. [PubMed: 25763862]
33.: Danese S, Fiorino G, Peyrin-Biroulet L, Lucenteforte E, Virgili G, Moja L, et al. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med. 2014 May 20;160(10):704–11. [PubMed: 24842416]
34.: Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, et al. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014 Apr;39(7):660–71. [PMC free article: PMC6979320] [PubMed: 24506179]
35.: Galvan-Banqueri M, Vega-Coca MD, Castillo-Munoz MA, Beltran CC, Molina LT. Indirect comparison for Anti-TNF drugs in moderate to severe ulcerative colitis. Farm Hosp [Internet]. 2015 Mar [cited 2015 Nov 16];39(2):80–91. Available from: http://www.aulamedica.es/fh/pdf/8218.pdf [PubMed: 25817087]

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK539019

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Clinical Review Report: adalimumab (Humira) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr. References.
PDF version of this title (962K)